吉西他滨联合顺铂治疗蒽环类及紫杉类耐药性晚期乳腺癌疗效分析

Efficacy of Gemcitabine Combined with Cisplatin in the Treatment of Advanced Breast Cancer with Advanced Breast Cancer

目的研究并分析吉西他滨联合顺铂治疗蒽环类及紫杉类耐药性晚期乳腺癌的疗效,为临床上乳腺癌的治疗提供有效方法。方法将收治的80例乳腺癌患者纳入研究对象,均为蒽环类及紫杉类耐药性患者。并随机分为两组,每组患者各40例,参照组采用长春瑞滨联合顺铂方案治疗,试验组采用吉西他滨联合顺铂方案治疗。观察患者的治疗效果、不良反应发生情况。结果试验组治疗临床缓解率为40.0%,临床控制率为67.5%,明显高于参照组的22.5%和40.0%,差异具有统计学意义(P<0.05);参照组严重毒副反应发生率明显高于试验组,差异有统计学意义(P<0.05)。结论吉西他滨联合顺铂治疗蒽环类及紫杉类耐药性晚期乳腺癌疗效显著,有利于改善患者症状,提高其缓解率,且不会增加毒副作用,安全性高。

Objective To study and analysis of curative effect of gemcitabine combined with cisplatin in treatment of anthracycline and taxane resistant advanced breast cancer,provide an effective method for treating breast cancer. Methods 80 cases of breast cancer patients in our hospital were included in the study object,both anthracycline and taxane resistant patients. And randomly divided into two groups,each of the 40 cases of patients,the reference group by Changchun vinorelbine and cisplatin in the treatment,the experiment group adopted the gemcitabine plus cisplatin regimen in the treatment of. The occurrence of the treatment effect,to observe the patient＇s adverse reactions. Results Experimental group therapy clinical remission rate was 40%,the clinical control rate was 67. 5%,significantly higher than the reference group of 22. 5% and 40%,with significant difference（ P 〈0. 05）; reference group serious toxic side reaction rate was significantly higher than that of the test group,the difference was statistically significant（ P 〈0. 05）. Conclusions Gemcitabine plus cisplatin significantly in treatment of anthracycline and taxane resistant advanced breast cancer curative effect,is beneficial to improve symptoms,improve the response rate,and not increase side effects,high safety.